Drug intelligence / Profile preview

stavudine + lamivudine + nevirapine

Development stage
Phase 4
Lead developer
Cipla
Modality
Small Molecules
Administration
Oral
01

Overview

Stavudine + lamivudine + nevirapine is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. It contains three active ingredients: - Lamivudine and stavudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by causing DNA chain termination after being phosphorylated to their active forms inside cells. - Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase and blocks its RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site. This combination reduces viral replication and increases CD4 cell counts. It is commonly used as first-line therapy in resource-limited settings and is included on the World Health Organization's List of Essential Medicines[1][2][5].

Brand names
TriomuneVirolansNevilastNevilast BabyNevilast JuniorNexvir SStavex LNTrivirEmduo N
Other names
lamivudine/nevirapine/stavudine
02

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on stavudine + lamivudine + nevirapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on stavudine + lamivudine + nevirapine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call